Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-TRAC adjuvant sunitinib versus placebo in high-risk renal cell carcinoma
2006-004024-37Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Adjuvant Sutent with Placebo (2 arms). Primary endpoint: Disease-free survival. Started May 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2006-004024-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004024-37.